Selected Antimicrobial Information – Equine

Cefotaxime [Equine]

Restriction Status



Species Usage Dose
For susceptible infections in neonatal foals 20-40mg/kg IV q6-12h (extra-label use)
For meningitis in neonatal foals 40mg/kg IV q6h (extra-label use)
For regional limb perfusion in foals 1g per 20mL 0.9% NaCl for 20min (extra-label use)

Brand Name(s)



Cefotaxime is a bactericidal, time-dependent third generation cephalosporin (╬▓-lactam) antibiotic with increased activity against Gram-negative bacteria such as Enterobacteriaceae when compared to first and second generation cephalosporins (e.g. cefazolin). It is not effective against Enterococcus spp. and Pseudomonas aeruginosa, and has less efficacy against anaerobes than second generation cephalosporins. Distribution throughout the body is wide, and cefotaxime crosses the blood-brain barrier. Excretion is primarily in urine.

Acceptable Uses

  • Empirical treatment of sepsis or meningitis in neonatal foals; culture/susceptibility should be performed to further guide treatment.
  • Treatment of susceptible septic arthritis in foals.

Unacceptable Uses

  • N/A

Formulations Available within the OSU Pharmacy

  • Cefotaxime 10g/100ml injectable suspension


  • None.


Icon for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

OSU VMC Antimicrobial Use Guidelines Copyright © 2018 by The Ohio State University College of Veterinary Medicine is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, except where otherwise noted.